Biotinylated Human IGF-I Protein, His,Avitag? (SPR verified)
分子別名(Synonym)
IGF-I,IGF1A,somatomedin C,MGF
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Biotinylated Human IGF-I, His,Avitag (IG1-H82Q6) is expressed from human 293 cells (HEK293). It contains AA Gly 49 - Ala 118 (Accession # P05019-1).
Predicted N-terminus: His
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 11.2 kDa. The protein migrates as 14 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
標(biāo)記(Labeling)
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標(biāo)記度(Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
胰島素樣生長因子1(IGF-1)也稱為生長因子C、IGF1A、IGFI、硫酸化因子,是一種分子結(jié)構(gòu)與胰島素相似的激素。它在兒童成長中起著重要作用,并在成人中繼續(xù)具有合成代謝作用。mecasermin是IGF-1的合成類似物,用于治療生長衰竭。IGF-1由單鏈中的70個(gè)氨基酸組成,具有三個(gè)分子內(nèi)二硫鍵。IGF-1的分子量為7649道爾頓。IGF-1主要由肝臟作為內(nèi)分泌激素產(chǎn)生,也以旁分泌/自分泌的方式在靶組織中產(chǎn)生。IGF-1與至少兩種細(xì)胞表面受體結(jié)合:胰島素樣生長因子1受體(縮寫為“IGF1R”)和胰島素受體。IGF-1受體似乎是“生理”受體——它與IGF-1的親和力明顯高于與胰島素受體結(jié)合的IGF-1。與胰島素受體一樣,IGF-1受體是一種受體酪氨酸激酶,這意味著它通過在特定的酪氨酸上添加磷酸分子來發(fā)出信號(hào)。其主要作用是通過與其特異性受體IGF1R結(jié)合來介導(dǎo)的,IGF1R存在于許多組織中的許多細(xì)胞類型上。與受體酪氨酸激酶IGF1R結(jié)合,啟動(dòng)細(xì)胞內(nèi)信號(hào)傳導(dǎo);IGF-1是AKT信號(hào)通路最有效的天然激活劑之一,是細(xì)胞生長和增殖的刺激劑,也是程序性細(xì)胞死亡的強(qiáng)效抑制劑。胰島素樣生長因子1已被證明與所有IGF-1結(jié)合蛋白(IGFBPs)結(jié)合并相互作用,其中有六種(IGFBP1-6)。提供了與IGFBP3、IGFBP4和IGFBP7相互作用的具體參考文獻(xiàn)。
關(guān)鍵字: IGF-I;IGF-I蛋白;IGF-I重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。